普萘洛尔治疗婴幼儿面部血管瘤的初步观察  

Preliminary Study on Propranolol Treatment in Infantile Facial Hemangiomas

作　　者：纪影畅[1] 蔡湘娜[1] 许宏权[1] 李宏生[1] 肖洋[1] 李宇[1] 

机构地区：[1]汕头大学医学院第一附属医院整形科,广东汕头515041

出　　处：《汕头大学医学院学报》2012年第1期27-29,F0003,共4页Journal of Shantou University Medical College

摘　　要：目的:观察普萘洛尔治疗婴幼儿面部血管瘤的疗效和安全性。方法:将血管瘤患儿分为观察组(27例)和对照组(19例)。观察组予普萘洛尔,第1 d 0.5 mg.kg-1.d-1,第2 d 1 mg.kg-1.d-1,第3 d 2 mg.kg-1.d-1,分3次口服,无异常情况继续用药2 mg.kg-1.d-112周。对照组予泼尼松3 mg.kg-1.d-1,隔天早晨一次顿服,共服8周,第9周减量1/2,第10周每次服药10 mg,第11周每次服药5 mg,第12周停服完成1个疗程。结果:观察组有效率92.6%,对照组57.9%(P<0.05)。结论:普萘洛尔治疗婴幼儿面部血管瘤效果比泼尼松显著,治疗过程不良反应少,安全性较高,可作为婴幼儿面部血管瘤的一线用药。Objective： To study the efficacy and safety of propranolol treatment in infantile facial hemangiomas. Methods： The infantile patients（46 cases）with facial hemangiomas were classified into observation group and control group. The observation group was orally administered propranolol, started at 0.5 mg. kg- 1. d- 1, then gradually increased to reach a dosage of 2 mg.kg-1.d-1 on the third day. The dosage was maintained at 2 mg.kg-1.d-1 in the following 12 weeks. The control group was administered prednisone treatment at 3 mg. kg- 1. d- 1 by once every other day for 8 weeks, then reduced to zero from week 9 to 12 step by step. Results： The effective rate in the obserration group was 92.6%, 57.9% in the control group（ P 〈 0.05）. Conclusion： The efficacy and safety of propranolol treatment in infantile facial hemangiomas is significantly higher than that of prednisone treatment, we propose the use of propranolol as first-line treat- ment for infantile facial hemangiomas.

关 键 词：普萘洛尔 泼尼松 血管瘤 婴幼儿 

分 类 号：R739.5[医药卫生—肿瘤]